{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:29:13Z","timestamp":1792787353286,"version":"4.5.0"},"reference-count":162,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Radiotherapy (RT) plays a diverse and essential role in the contemporary management of non-Hodgkin lymphoma (NHL) and remains the single most powerful monotherapeutic intervention for both aggressive and indolent subtypes. Over the past decade, there have been significant advancements in radiation oncology practice, which have made modern treatments safer and more conformal. Despite this sophistication and evidence supporting a continued role for RT, numerous data suggest that utilization is on the decline. In this review, we discuss the rationale for RT in 4 commonly encountered scenarios: combined modality therapy for limited-stage aggressive NHL, consolidation therapy for advanced-stage aggressive NHL, and the changing roles of salvage RT for relapsed\/refractory NHL in an era of new frontiers such as cellular therapies. We also evaluate current strategies to treat indolent histologies. We conclude with perspectives on how RT for the hematological malignancies may continue to evolve.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000453","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T21:02:18Z","timestamp":1591909338000},"page":"217-230","source":"Crossref","is-referenced-by-count":26,"title":["Radiotherapy for Non-Hodgkin Lymphomas"],"prefix":"10.1097","volume":"26","author":[{"given":"Brandon S.","family":"Imber","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Yahalom","sequence":"additional","affiliation":[{"name":"Lymphoma Disease Management Team Memorial Sloan Kettering Cancer Center, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20230924","first-page":"1129","article-title":"Radiation therapy of localized non-Hodgkin's lymphoma","volume":"61","year":"1977","journal-title":"Cancer Treat Rep"},{"key":"bib2-20230924","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0167-8140(85)80086-4","article-title":"Role of radiation therapy in localized non-Hodgkin's lymphoma","volume":"4","year":"1985","journal-title":"Radiother Oncol"},{"key":"bib4-20230924","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s11864-014-0286-4","article-title":"Radiotherapy of follicular lymphoma: updated role and new rules","volume":"15","year":"2014","journal-title":"Curr Treat Options Oncol"},{"key":"bib5-20230924","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1200\/JOP.18.00519","article-title":"Times not to forget radiotherapy when treating patients with lymphoma","volume":"15","year":"2019","journal-title":"J Oncol Pract"},{"key":"bib6-20230924","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1200\/JOP.19.00107","article-title":"Radiotherapy should be part of a multidisciplinary discussion for most patients with lymphoma","volume":"15","year":"2019","journal-title":"J Oncol Pract"},{"key":"bib7-20230924","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrclinonc.2016.211","article-title":"Radiotherapy and immunotherapy: a beneficial liaison?","volume":"14","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"bib8-20230924","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3389\/fonc.2018.00612","article-title":"Radiation, immune checkpoint blockade and the abscopal effect: a critical review on timing, dose and fractionation","volume":"8","year":"2018","journal-title":"Front Oncol"},{"key":"bib9-20230924","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrclinonc.2016.205","article-title":"The landscape of new drugs in lymphoma","volume":"14","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"suppl 1","key":"bib10-20230924","first-page":"105","article-title":"New drugs for new targets in lymphoma","volume":"37","year":"2019","journal-title":"Hematol Oncol"},{"key":"bib11-20230924","doi-asserted-by":"crossref","first-page":"S236","DOI":"10.1016\/S0167-8140(16)31746-7","article-title":"SP-0496: indications to radiotherapy for lymphoma in 2016: what is standard of care and what remains controversial?","volume":"119","year":"2016","journal-title":"Radiother Oncol"},{"key":"bib12-20230924","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijrobp.2014.01.006","article-title":"Modern radiation therapy for nodal non-Hodgkin lymphoma\u2014target definition and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"89","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib13-20230924","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1200\/JCO.2015.61.7654","article-title":"Treatment selection and survival outcomes in early-stage diffuse large B-cell lymphoma: do we still need consolidative radiotherapy?","volume":"33","year":"2015","journal-title":"J Clin Oncol"},{"key":"bib14-20230924","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":"Follicular lymphoma in the United States: first report of the national LymphoCare study","volume":"27","year":"2009","journal-title":"J Clin Oncol"},{"key":"bib15-20230924","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2141.2011.08713.x","article-title":"Review of the cardiac long-term effects of therapy for Hodgkin lymphoma","volume":"154","year":"2011","journal-title":"Br J Haematol"},{"key":"bib16-20230924","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.ijrobp.2017.03.026","article-title":"Late cardiac toxicity after Mediastinal radiation therapy for Hodgkin lymphoma: contributions of coronary artery and whole heart dose-volume variables to risk prediction","volume":"98","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib17-20230924","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1200\/JCO.2010.32.8427","article-title":"Long-term complications of lymphoma and its treatment","volume":"29","year":"2011","journal-title":"J Clin Oncol"},{"key":"bib18-20230924","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11912-015-0472-y","article-title":"Consolidative radiation in DLBCL: evidence-based recommendations","volume":"17","year":"2015","journal-title":"Curr Oncol Rep"},{"key":"bib19-20230924","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1200\/JCO.2005.04.2200","article-title":"Risk of second malignancy after non-Hodgkin's lymphoma: a British cohort study","volume":"24","year":"2006","journal-title":"J Clin Oncol"},{"key":"bib20-20230924","first-page":"1481","article-title":"Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study","volume":"91","year":"2006","journal-title":"Haematologica"},{"key":"bib21-20230924","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3324\/haematol.12918","article-title":"Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study","volume":"93","year":"2008","journal-title":"Haematologica"},{"key":"bib22-20230924","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3324\/haematol.12120","article-title":"Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study","volume":"93","year":"2008","journal-title":"Haematologica"},{"key":"bib23-20230924","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10147-013-0556-3","article-title":"Evolution of the techniques of radiation therapy in the management of lymphoma","volume":"18","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"bib24-20230924","doi-asserted-by":"crossref","first-page":"b4606","DOI":"10.1136\/bmj.b4606","article-title":"Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort","volume":"339","year":"2009","journal-title":"BMJ"},{"key":"bib25-20230924","doi-asserted-by":"crossref","first-page":"e492","DOI":"10.1016\/S2352-3026(15)00153-2","article-title":"Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials","volume":"2","year":"2015","journal-title":"Lancet Haematol"},{"key":"bib26-20230924","article-title":"ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic","year":"2020","journal-title":"Blood"},{"key":"bib27-20230924","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM199807023390104","article-title":"Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"bib28-20230924","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1200\/JCO.2015.65.4582","article-title":"Continued risk of relapse independent of treatment modality in limited-stage diffuse large B-cell lymphoma: final and long-term analysis of Southwest Oncology Group Study S8736","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib29-20230924","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1200\/JCO.2007.13.6929","article-title":"Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group Study 0014","volume":"26","year":"2008","journal-title":"J Clin Oncol"},{"key":"bib30-20230924","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3109\/10428194.2014.930853","article-title":"Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients","volume":"56","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"bib31-20230924","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/cncr.29113","article-title":"Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project","volume":"121","year":"2015","journal-title":"Cancer"},{"key":"bib32-20230924","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1200\/JCO.2009.27.3441","article-title":"Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy","volume":"28","year":"2010","journal-title":"J Clin Oncol"},{"key":"bib33-20230924","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","article-title":"Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial","volume":"100","year":"2011","journal-title":"Radiother Oncol"},{"key":"bib34-20230924","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10147-015-0863-y","article-title":"The concept and evolution of involved site radiation therapy for lymphoma","volume":"20","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"bib35-20230924","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijrobp.2015.01.009","article-title":"Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"92","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib36-20230924","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijrobp.2015.01.008","article-title":"International lymphoma radiation oncology group. Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"92","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib37-20230924","article-title":"Involved site radiation therapy in adult lymphomas: an overview of International Lymphoma Radiation Oncology Group guidelines","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib38-20230924","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.beha.2018.07.009","article-title":"Successful role of radiation therapy: account for every single gray and make every single gray count","volume":"31","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"bib39-20230924","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","year":"2015","journal-title":"Blood"},{"key":"bib40-20230924","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1182\/blood-2017-07-793984","article-title":"R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma","volume":"131","year":"2018","journal-title":"Blood"},{"key":"bib41-20230924","first-page":"2271","article-title":"Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial","volume":"394","year":"2020","journal-title":"Lancet"},{"key":"bib42-20230924","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera international trial (MInT) group","volume":"12","year":"2011","journal-title":"Lancet Oncol"},{"key":"bib43-20230924","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","year":"2008","journal-title":"Lancet Oncol"},{"key":"bib44-20230924","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2013.51.4505","article-title":"Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma","volume":"32","year":"2014","journal-title":"J Clin Oncol"},{"key":"bib45-20230924","doi-asserted-by":"crossref","first-page":"7574","DOI":"10.1200\/JCO.2018.36.15_suppl.7574","article-title":"Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6\u00d7R-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: results of the 2\u00d72 randomized UNFOLDER trial of the DSHNHL\/GLA","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"key":"bib46-20230924","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1200\/JCO.2012.48.0467","article-title":"Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement","volume":"31","year":"2013","journal-title":"J Clin Oncol"},{"key":"bib47-20230924","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijrobp.2015.01.014","article-title":"Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma","volume":"92","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib48-20230924","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/blood-2013-10-530659","article-title":"Primary testicular lymphoma","volume":"123","year":"2014","journal-title":"Blood"},{"key":"bib49-20230924","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/bjh.14392","article-title":"Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era","volume":"176","year":"2017","journal-title":"Br J Haematol"},{"key":"bib50-20230924","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1080\/10428194.2017.1312381","article-title":"Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma<sup\/>","volume":"58","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"bib51-20230924","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.6004\/jnccn.2016.0121","article-title":"Risk factors for early death after rituximab-based immunochemotherapy in older patients with diffuse large B-cell lymphoma","volume":"14","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"bib52-20230924","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.bbmt.2014.08.019","article-title":"Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma","volume":"20","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"bib53-20230924","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.3109\/10428194.2015.1120866","article-title":"The role of radiotherapy for patients over age 60 with diffuse large B-cell lymphoma in the rituximab era","volume":"57","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"bib54-20230924","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1080\/10428194.2016.1205739","article-title":"Older patients with early-stage diffuse large B-cell lymphoma: the role of consolidation radiotherapy after chemoimmunotherapy","volume":"58","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"bib55-20230924","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.1200\/JCO.2017.35.15_suppl.7506","article-title":"Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"key":"bib56-20230924","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.3109\/10428194.2011.585526","article-title":"Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma","volume":"52","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"bib57-20230924","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ijrobp.2013.02.007","article-title":"Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy","volume":"86","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib58-20230924","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/pro6.1071","article-title":"Role of radiotherapy in diffuse large B-cell lymphoma in advanced stages on complete response after administration of cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab","volume":"3","year":"2019","journal-title":"Precis Radiat Oncol"},{"key":"bib59-20230924","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.ijrobp.2011.12.067","article-title":"Impact of consolidation radiation therapy in stage III\u2013IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging","volume":"84","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib60-20230924","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1182\/blood-2016-05-672196","article-title":"Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: do we trust the driver?","volume":"129","year":"2017","journal-title":"Blood"},{"key":"bib61-20230924","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00259-018-4103-3","article-title":"Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis","volume":"46","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib62-20230924","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/blood.V130.Suppl_1.823.823","article-title":"Long-term results of PET-guided radiation therapy in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP in British Columbia","volume":"130","year":"2017","journal-title":"Blood"},{"key":"bib63-20230924","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ijrobp.2019.02.001","article-title":"The optimal use of imaging in radiation therapy for lymphoma: guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"104","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib64-20230924","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.3109\/10428194.2013.784967","article-title":"Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma","volume":"54","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"bib65-20230924","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","year":"2017","journal-title":"Blood"},{"key":"bib66-20230924","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ijrobp.2017.12.005","article-title":"Role of radiation therapy in patients with relapsed\/refractory diffuse large B-cell lymphoma: guidelines from the International Lymphoma Radiation Oncology Group","volume":"100","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib67-20230924","doi-asserted-by":"crossref","first-page":"100640","DOI":"10.1016\/j.blre.2019.100640","article-title":"Modern management of relapsed and refractory aggressive B-cell lymphoma: a perspective on the current treatment landscape and patient selection for CAR T-cell therapy","volume":"40","year":"2020","journal-title":"Blood Rev"},{"key":"bib68-20230924","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","year":"1995","journal-title":"N Engl J Med"},{"key":"bib69-20230924","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","year":"2010","journal-title":"J Clin Oncol"},{"key":"bib70-20230924","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM198706113162401","article-title":"High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"bib71-20230924","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0360-3016(97)00379-9","article-title":"High dose chemotherapy and stem cell rescue for aggressive non-Hodgkin's lymphoma: pattern of failure and implications for involved-field radiotherapy","volume":"39","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib72-20230924","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1200\/JCO.2001.19.2.406","article-title":"Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the autologous blood and marrow transplant registry","volume":"19","year":"2001","journal-title":"J Clin Oncol"},{"key":"bib73-20230924","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1083-8791(01)80012-4","article-title":"The impact of external beam radiation therapy prior to autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma","volume":"7","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"bib74-20230924","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/bmt.2008.408","article-title":"The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma","volume":"43","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"bib75-20230924","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijrobp.2009.04.036","article-title":"Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era","volume":"77","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib76-20230924","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/j.ijrobp.2015.07.157","article-title":"Role of consolidative radiation therapy following autologous stem cell transplant for relapsed or refractory diffuse large B-cell lymphoma","volume":"93","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib77-20230924","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ijrobp.2016.05.021","article-title":"Patterns and timing of failure for diffuse large B-cell lymphoma after initial therapy in a cohort who underwent autologous bone marrow transplantation for relapse","volume":"96","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib78-20230924","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/01.coc.0000251242.32763.35","article-title":"The impact of involved field radiation therapy in the treatment of relapsed or refractory non-Hodgkin lymphoma with high-dose chemotherapy followed by hematopoietic progenitor cell transplant","volume":"30","year":"2007","journal-title":"Am J Clin Oncol"},{"key":"bib79-20230924","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/bjh.14453","article-title":"Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era","volume":"176","year":"2017","journal-title":"Br J Haematol"},{"key":"bib80-20230924","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1200\/JCO.2007.15.4773","article-title":"Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity","volume":"26","year":"2008","journal-title":"J Clin Oncol"},{"key":"bib81-20230924","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/sj.leu.2402342","article-title":"Positron emission tomography with [18F]2-fluoro-d-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation","volume":"16","year":"2002","journal-title":"Leukemia"},{"key":"bib82-20230924","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2002-12-3842","article-title":"Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation","volume":"102","year":"2003","journal-title":"Blood"},{"key":"bib83-20230924","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2141.2010.08162.x","article-title":"Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy: research paper","volume":"150","year":"2010","journal-title":"Br J Haematol"},{"key":"bib84-20230924","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/bjh.12176","article-title":"Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era","volume":"160","year":"2013","journal-title":"Br J Haematol"},{"key":"bib85-20230924","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3109\/10428194.2013.797974","article-title":"Predictive value of [18F]fluoro-2-deoxy-d-glucose positron emission tomography for clinical outcome in patients with relapsed\/refractory diffuse large B-cell lymphoma prior to and after autologous stem cell transplant","volume":"55","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"bib86-20230924","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2014-10-606939","article-title":"Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma","volume":"125","year":"2015","journal-title":"Blood"},{"key":"bib87-20230924","first-page":"3599","article-title":"Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation","volume":"92","year":"1998","journal-title":"Blood"},{"key":"bib88-20230924","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/sj.bmt.1704759","article-title":"Optimal scheduling to reduce morbidity of involved field radiotherapy with transplantation for lymphomas: a prospective Australasian Leukaemia and Lymphoma Group Study","volume":"35","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"bib89-20230924","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ijrobp.2011.05.078","article-title":"Predictive factors for radiation pneumonitis in Hodgkin lymphoma patients receiving combined-modality therapy","volume":"83","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib90-20230924","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijrobp.2015.02.010","article-title":"Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma","volume":"92","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"S2","key":"bib91-20230924","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hon.69_2630","article-title":"Highly Favorable outcomes with RT followed by ASCT in low\/low-intermediate secondary age adjusted IPI REL\/REF DLBCL patients refractory to salvage chemotherapy","volume":"37","year":"2019","journal-title":"Hematol Oncol"},{"key":"bib92-20230924","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"key":"bib93-20230924","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"bib94-20230924","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","year":"2019","journal-title":"Lancet Oncol"},{"key":"bib95-20230924","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","year":"2019","journal-title":"N Engl J Med"},{"key":"bib96-20230924","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2019-127508","article-title":"Pivotal safety and efficacy results from Transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed\/refractory (R\/R) large B cell lymphomas","volume":"134","year":"2019","journal-title":"Blood"},{"key":"bib97-20230924","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1182\/blood-2019-129624","article-title":"Characteristics and outcomes of patients receiving bridging therapy while awaiting manufacture of standard of care axicabtagene ciloleucel CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium","volume":"134","year":"2019","journal-title":"Blood"},{"key":"bib98-20230924","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1182\/blood-2019-124492","article-title":"Correlation of bridging and lymphodepleting chemotherapy with clinical outcomes in patients with relapsed\/refractory diffuse large B-cell lymphoma treated with tisagenlecleucel","volume":"134","year":"2019","journal-title":"Blood"},{"key":"bib99-20230924","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1182\/blood-2018-99-117199","article-title":"Axicabtagene ciloleucel in the real world: outcomes and predictors of response, resistance and toxicity","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib100-20230924","doi-asserted-by":"crossref","first-page":"7562","DOI":"10.1200\/JCO.2019.37.15_suppl.7562","article-title":"Association of high baseline metabolic tumor volume with response following axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib101-20230924","article-title":"Early experience using salvage radiotherapy for relapsed\/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy","year":"2020","journal-title":"Br J Haematol"},{"key":"bib102-20230924","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/j.ijrobp.2019.06.515","article-title":"Patterns of failure following chimeric antigen receptor T-cell (CAR-T) therapy","volume":"105","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib103-20230924","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/2051013617750561","article-title":"The influence of radiation in the context of developing combination immunotherapies in cancer","volume":"5","year":"2017","journal-title":"Ther Adv Vaccines Immunother"},{"key":"bib104-20230924","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","year":"2015","journal-title":"Nature"},{"key":"bib105-20230924","first-page":"159","article-title":"Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART)","volume":"6","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"bib106-20230924","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/imr.12773","article-title":"CAR T cells for brain tumors: lessons learned and road ahead","volume":"290","year":"2019","journal-title":"Immunol Rev"},{"key":"bib107-20230924","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.copbio.2020.01.009","article-title":"All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy","volume":"65","year":"2020","journal-title":"Curr Opin Biotechnol"},{"key":"bib108-20230924","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1016\/j.ijrobp.2016.06.310","article-title":"Radiation sensitizes tumor cells to CAR T cell immunotherapy","volume":"96","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib109-20230924","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.ymthe.2018.09.008","article-title":"Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape","volume":"26","year":"2018","journal-title":"Mol Ther"},{"key":"bib110-20230924","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1158\/2326-6066.CIR-18-0551","article-title":"BCMA-targeted CAR T-cell therapy plus radiation therapy for the treatment of refractory myeloma reveals potential synergy","volume":"7","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"S2","key":"bib111-20230924","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/hon.68_2630","article-title":"Mskcc early experience using radiotherapy as a bridging strategy for relapsed diffuse large B cell lymphoma before CD19 CAR T therapy","volume":"37","year":"2019","journal-title":"Hematol Oncol"},{"key":"bib112-20230924","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.ijrobp.2019.05.065","article-title":"Radiation therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-cell lymphoma","volume":"105","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib113-20230924","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1182\/blood-2019-131499","article-title":"Radiation therapy can be an effective bridging strategy prior to axicabtagene ciloleucel therapy for relapsed\/refractory large B-cell lymphoma","volume":"134","year":"2019","journal-title":"Blood"},{"key":"bib114-20230924","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1016\/j.ijrobp.2018.06.306","article-title":"Tandem induction radiation and chimeric antigen receptor T cell therapy in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"102","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib115-20230924","first-page":"E209","article-title":"Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy","volume":"94","year":"2019","journal-title":"Am J Hematol"},{"key":"bib116-20230924","doi-asserted-by":"crossref","first-page":"7517","DOI":"10.1200\/JCO.2019.37.15_suppl.7517","article-title":"Outcomes in large B-cell lymphoma progressing after axicabtagene ciloleucel (Axi-cel): results from the U.S. Lymphoma CAR-T Consortium","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib117-20230924","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1016\/j.bbmt.2019.06.036","article-title":"Understanding and managing large B cell lymphoma relapses after chimeric antigen receptor T cell therapy","volume":"25","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"bib118-20230924","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrd.2018.74","article-title":"The global landscape of cancer cell therapy","volume":"17","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"bib119-20230924","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1182\/bloodadvances.2018026401","article-title":"Outcomes of patients with relapsed\/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy","volume":"3","year":"2019","journal-title":"Blood Adv"},{"key":"bib120-20230924","first-page":"155","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib121-20230924","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2019-123742","article-title":"Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines","volume":"134","year":"2019","journal-title":"Blood"},{"key":"bib122-20230924","first-page":"4121","article-title":"Phase I\/II study of pembrolizumab for progressive diffuse large B cell lymphoma after anti-CD19 directed chimeric antigen receptor modified T cell therapy","volume":"130","year":"2017","journal-title":"Blood"},{"key":"bib123-20230924","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.bbmt.2019.12.771","article-title":"Cellular immunotherapy for refractory diffuse large B cell lymphoma in the chimeric antigen receptor\u2013engineered T cell era: still a role for allogeneic transplantation?","volume":"26","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"bib124-20230924","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijrobp.2014.09.041","article-title":"Rates and durability of response to salvage radiation therapy among patients with refractory or relapsed aggressive non-Hodgkin lymphoma","volume":"91","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib125-20230924","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1200\/JCO.1996.14.4.1282","article-title":"Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University","volume":"14","year":"1996","journal-title":"J Clin Oncol"},{"key":"bib126-20230924","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0360-3016(01)01747-3","article-title":"Long-term results with radiotherapy for stage I\u2013II follicular lymphomas","volume":"51","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib127-20230924","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/blood-2018-04-843540","article-title":"Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG","volume":"133","year":"2019","journal-title":"Blood"},{"key":"bib128-20230924","article-title":"Long-term outcomes for patients with limited-stage follicular lymphoma: update of a population-based study","year":"2020","journal-title":"Blood"},{"key":"bib129-20230924","doi-asserted-by":"crossref","first-page":"e2016041","DOI":"10.4084\/mjhid.2016.041","article-title":"Limited stage follicular lymphoma: current role of radiation therapy","volume":"8","year":"2016","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"bib130-20230924","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1002\/1097-0142(19831215)52:12<2300::AID-CNCR2820521224>3.0.CO;2-Y","article-title":"Analysis of non-Hodgkin's lymphomas with nodular and favorable histologies, stages I and II","volume":"52","year":"1983","journal-title":"Cancer"},{"key":"bib131-20230924","first-page":"66","article-title":"Stage I\u2013II low grade non-Hodgkin's lymphoma: prognostic factors and treatment results","volume":"168","year":"1992","journal-title":"Strahlenther Onkol"},{"key":"bib132-20230924","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1002\/cncr.25117","article-title":"Long-term outcomes for patients with limited stage follicular lymphoma","volume":"116","year":"2010","journal-title":"Cancer"},{"key":"bib133-20230924","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1200\/JCO.2011.40.6546","article-title":"Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the national LymphoCare study","volume":"30","year":"2012","journal-title":"J Clin Oncol"},{"key":"bib134-20230924","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/cncr.21967","article-title":"Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas","volume":"107","year":"2006","journal-title":"Cancer"},{"key":"bib135-20230924","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijrobp.2007.09.051","article-title":"Impact of [18F] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma","volume":"71","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib136-20230924","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00259-008-0958-z","article-title":"Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study","volume":"36","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib137-20230924","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1007\/s00259-010-1539-5","article-title":"Diagnostic and prognostic impact of 18F-FDG PET\/CT in follicular lymphoma","volume":"37","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib138-20230924","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ijrobp.2019.03.004","article-title":"Salvage treatment and survival for relapsed follicular lymphoma following primary radiation therapy: a collaborative study on behalf of ILROG","volume":"104","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib139-20230924","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1182\/bloodadvances.2019000458","article-title":"Outcomes of stage I\/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance","volume":"3","year":"2019","journal-title":"Blood Adv"},{"key":"bib140-20230924","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2018.77.9892","article-title":"Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"key":"bib141-20230924","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1200\/JCO.2003.07.111","article-title":"Long-term follow-up of a prospective study of combined modality therapy for stage I\u2013II indolent non-Hodgkin's lymphoma","volume":"21","year":"2003","journal-title":"J Clin Oncol"},{"key":"bib142-20230924","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ijrobp.2015.12.019","article-title":"Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I\u2013II follicular lymphoma: results of a multicenter study","volume":"94","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib143-20230924","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.2018.79.3075","article-title":"Early-stage follicular lymphoma: what is the preferred treatment strategy?","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"key":"bib144-20230924","doi-asserted-by":"crossref","first-page":"6619","DOI":"10.1200\/JCO.2017.35.15_suppl.6619","article-title":"Cost-effectiveness analysis of first-line treatments for early-stage, low-grade follicular lymphoma","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"key":"bib145-20230924","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1182\/blood-2019-132275","article-title":"Outcomes of 210 patients with follicular and marginal zone lymphomas treated with 4 Gy of radiation therapy","volume":"134","year":"2019","journal-title":"Blood"},{"key":"bib146-20230924","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijrobp.2012.12.024","article-title":"Low-dose involved-field radiation in the treatment of non-Hodgkin lymphoma: predictors of response and treatment failure","volume":"86","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib147-20230924","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1470-2045(14)70036-1","article-title":"4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial","volume":"15","year":"2014","journal-title":"Lancet Oncol"},{"key":"bib148-20230924","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","year":"2018","journal-title":"Nat Med"},{"key":"bib149-20230924","first-page":"445","article-title":"DLBCL cell of origin: what role should it play in care today?","volume":"32","year":"2018","journal-title":"Oncology (Williston Park)"},{"key":"bib150-20230924","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1080\/10428194.2018.1506586","article-title":"Radiotherapy for early stage diffuse large B-cell lymphoma with or without double or triple hit genetic alterations","volume":"60","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"bib151-20230924","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.prro.2019.09.013","article-title":"Impact of double- or triple-hit pathology on rates and durability of radiation therapy response among patients with relapsed or refractory large B-cell lymphoma","volume":"10","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"bib152-20230924","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.critrevonc.2018.11.009","article-title":"Safety and efficacy of combined radiotherapy, immunotherapy and targeted agents in elderly patients: a literature review","volume":"133","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"bib153-20230924","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1080\/09553002.2019.1623429","article-title":"Radiation therapy to enhance tumor immunotherapy: a novel application for an established modality","volume":"95","year":"2019","journal-title":"Int J Radiat Biol"},{"key":"bib154-20230924","doi-asserted-by":"crossref","first-page":"93","DOI":"10.21037\/tcr.2017.01.08","article-title":"The role of novel immunotherapies in non-Hodgkin lymphoma","volume":"6","year":"2017","journal-title":"Transl Cancer Res"},{"key":"bib155-20230924","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/ddg.14044","article-title":"Combined total skin radiotherapy and immune checkpoint inhibitors: a promising potential treatment for mycosis fungoides and Sezary syndrome","volume":"18","year":"2020","journal-title":"J Dtsch Dermatol Ges"},{"key":"bib156-20230924","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijrobp.2019.02.055","article-title":"Phase 2 study of dose-reduced consolidation radiation therapy in diffuse large B-cell lymphoma","volume":"105","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib157-20230924","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.ijrobp.2018.06.234","article-title":"Excellent outcomes after reduced-dose intensity modulated radiation therapy for gastric mucosa-associated lymphoid tissue (MALT) lymphoma","volume":"102","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib158-20230924","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ijrobp.2017.05.004","article-title":"Evidence-based review on the use of proton therapy in lymphoma from the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee","volume":"99","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib159-20230924","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2018-03-837633","article-title":"Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib160-20230924","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.3109\/10428194.2015.1014364","article-title":"Proton therapy in the management of non-Hodgkin lymphoma","volume":"56","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"bib161-20230924","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3857\/roj.2015.33.3.161","article-title":"Image-guided radiation therapy in lymphoma management","volume":"33","year":"2015","journal-title":"Radiat Oncol J"},{"key":"bib162-20230924","first-page":"80","article-title":"Financial toxicity, part I: a new name for a growing problem","volume":"27","year":"2013","journal-title":"Oncology (Williston Park)"},{"key":"bib163-20230924","doi-asserted-by":"crossref","first-page":"166","DOI":"10.21037\/atm.2018.03.28","article-title":"Financial toxicity and implications for cancer care in the era of molecular and immune therapies","volume":"6","year":"2018","journal-title":"Ann Transl Med"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000453","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T12:58:57Z","timestamp":1723035537000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":162,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000453","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}